Follow-The-Filings

Security · featured owners

OCUL Ocular Therapeutix Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 2 Owners
  • Max 0.5%
  • $7M
  • 1 reduce 1 exit

OCUL (Ocular Therapeutix Inc.) is held in 2 featured 13F books as of 2026 Q2. James Silverman - Opaleye Management is the largest tracked holder by portfolio weight (0.53%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 0.5% (James Silverman - Opaleye Management) · not free-float ownership

  1. James Silverman 0.53%
  2. Nehal Chopra Reduce 0.22%

Holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

History
James Silverman - Opaleye Management 2026 Q2 0.53% Hold 600,000 $6M History
Nehal Chopra - Ratan Capital Management 2026 Q2 0.22% Reduce −62.5% 70,792 $695K History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 18,000 $152K History

2 current · 1 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 9 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A Filing Doc
8-K 7.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 9 rows shown

Filed Form Detail Links
4 Period Aug 31, 2026 Filing Doc
4 Period Aug 24, 2026 · 4 forms Filing Doc
4 Period Jun 16, 2026 Filing Doc
4 Period Jun 10, 2026 · 7 forms Filing Doc
4 Period Jun 3, 2026 Filing Doc
4 Period May 26, 2026 · 4 forms Filing Doc
4 Period Apr 9, 2026 Filing Doc
4 Period Feb 23, 2026 · 4 forms Filing Doc
4 Period Feb 20, 2026 · 2 forms Filing Doc

Updated 19 days ago Source: SEC EDGAR submissions All on EDGAR

Financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $58.44M $63.72M $51.95M
Gross profit * $53.16M $58.1M $45.38M
Gross margin * 91.0% 91.2% 87.3%
Net income -$80.74M -$193.51M -$265.94M
Net margin * -138.1% -303.7% -511.9%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $232.24M $440.99M $782.13M
Total non-current assets * $19.82M $16.95M $25.93M
Total assets $252.06M $457.94M $808.06M
Total current liabilities $34.9M $41.35M $50.81M
Total non-current liabilities * $126.03M $101.24M $102.94M
Total equity $91.13M $315.34M $654.31M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$70.23M -$134.68M -$204.88M
Cash from investing -$6.09M -$1.29M -$11.88M
Cash from financing $169.83M $332.11M $561.72M
Net change in cash $93.51M $196.14M $344.96M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

Ownership over time

filing count by report period · click a bar for that quarter’s holders